Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome
The Journal of Clinical Endocrinology & Metabolism · 18.11.2025 · 110 (12) · 3525-3537
DOI: 10.1210/clinem/dgaf206 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 02.04.2025. Verfasst von Davide Ferrari und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, "Sapienza" University of Rome, Rome 00161, Italy. Hauptthemen laut MEDLINE: Quality of Life, Hydrocortisone, Cushing Syndrome, Circadian Rhythm. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-NextGenerationEU, Italian Ministry of University and Research, CUP.
Abstract (Originalsprache)
Context
Medical therapy for Cushing syndrome (CS) typically aims to reduce daily cortisol output without addressing circadian rhythm restoration. No licensed drugs target this goal.
Objective
We investigated the efficacy and safety of timed, once-daily osilodrostat administration in improving circadian cortisol profiles in CS.
Methods
A prospective, multicenter study evaluated patients with well-controlled CS on a stable twice-daily osilodrostat therapy before and 60 to 90 days after transitioning to a single equivalent daily dose at 19:00 ± 1 hour. Circadian steroid analysis was performed on saliva, serum, and urine using ultra-high performance liquid chromatography–tandem mass spectrometry. Additional assessments included cardio-metabolic markers, quality of life, sleep function, and safety outcomes.
Results
Sixteen patients (4 males; 7 pituitary, mean age 53.3 ± 11.8 years) were enrolled. At baseline, CS was well-controlled with a mean osilodrostat dose of 4.2 ± 1.3 mg. After transitioning, salivary cortisol exposure decreased significantly during the afternoon to early morning period (AUC16:00-08:00: −6.1 [−0.15 to −12.1] ng/mL/h, P = .029). Quality of life and sleep improved (CushingQoL: +4.2, P = .029; Pittsburgh Sleep Quality Index: −1.7, P = .049). Serum steroid precursors, including 11-deoxycorticosterone (−3.1 ng/mL/h, P = .008) and 11-deoxycortisol (−17.8 ng/mL/h, P = .005), decreased. Eight patients advancing dosing to 16:00 ± 1 hour showed comparable reductions, with phase shifts in acrophase and nadir. No patients developed adrenal insufficiency, liver toxicity, electrocardiogram abnormalities, or loss of disease control.
Conclusion
Once-daily osilodrostat effectively and safely treats patients with biochemically controlled CS, improving circadian cortisol profiles, quality of life, and sleep. Findings support further exploration of chronotherapy-based approaches in CS management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, "Sapienza" University of Rome, Rome 00161, Italy.
- Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università Federico II di Napoli, Naples 80131, Italy.
- Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.
- Centre for Rare Diseases (Endo-ERN Accredited), Policlinico Umberto I, Rome 00161, Italy.
ORCID-Profile: Davide Ferrari, Dario De Alcubierre, Marianna Minnetti, Emilia Sbardella, Rosario Pivonello, Daniele Gianfrilli, Andrea M Isidori
Förderung
- European Union-NextGenerationEU
- Italian Ministry of University and Research
- CUP
- Ministerial Research Project
- European Union—NextGenerationEU
Zitieren
APA
Ferrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., Minnetti, M., Sbardella, E., Venneri, M. A., Pofi, R., Pivonello, R., Gianfrilli, D., Hasenmajer, V., & Isidori, A. M. (2025). Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome. The Journal of Clinical Endocrinology & Metabolism, 110(12), 3525-3537. https://doi.org/10.1210/clinem/dgaf206
Vancouver
Ferrari D, Bonaventura I, Simeoli C, Tomaselli A, Vincenzi L, De Alcubierre D, et al. Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2025;110(12):3525-3537. doi:10.1210/clinem/dgaf206
BibTeX
@article{Ferrari2025,
author = {Ferrari, Davide and Bonaventura, Ilaria and Simeoli, Chiara and Tomaselli, Alessandra and Vincenzi, Ludovica and De Alcubierre, Dario and Sciarra, Francesca and Rizzo, Flavio and Cerroni, Lorenzo and Di Paola, Nicola and Minnetti, Marianna and Sbardella, Emilia and Venneri, Mary Anna and Pofi, Riccardo and Pivonello, Rosario and Gianfrilli, Daniele and Hasenmajer, Valeria and Isidori, Andrea M},
title = {Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {12},
pages = {3525--3537},
doi = {10.1210/clinem/dgaf206}
}
EUVIMED